Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 12:17:3307-3329.
doi: 10.2147/PPA.S427209. eCollection 2023.

Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema

Andrea Taloni #  1 , Giulia Coco #  2 , Davide Rastelli  3 , Giacinta Buffon  2 , Vincenzo Scorcia  1 , Giuseppe Giannaccare  4
Affiliations
Review

Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema

Andrea Taloni et al. Patient Prefer Adherence. .

Abstract

Diabetic macular edema (DME) is a common sight-threatening complication of diabetic retinopathy (DR) and the leading cause of severe visual impairment among the working-age population. Several therapeutic options are available for the management of DME, including intravitreal corticosteroids. They have been traditionally used as second-line treatment, due to the risk of intraocular pressure increase and cataract-related adverse events. However, attention has recently been focused on the primary or early use of intravitreal corticosteroids, due to growing evidence of the crucial role of inflammation in the pathogenesis of DME. Furthermore, intravitreal steroid implants offer the additional advantage of a longer duration of action compared to anti-vascular endothelial growth factor agents (anti-VEGF). This review aims to summarize the available evidence on the efficacy and safety profile of dexamethasone (DEX) intravitreal implant, with a specific focus on clinical scenarios in which it might be considered or even preferred as first-line treatment option by adequate selection of patients, considering both advantages and possible adverse events. Patients with contraindications to anti-VEGF, DME with high inflammatory OCT biomarkers, pseudophakic patients and phakic patients' candidates to cataract surgery as well as vitrectomized eyes may all benefit from first-line DEX implant. Additionally, DME not responders to anti-VEGF should be considered for a switch to DEX implant and a combination therapy of DEX implant and anti-VEGF could be a valid option in severe and persistent DME.

Keywords: DEX implant; DME; Ozurdex; corticosteroids; dexamethasone intravitreal implant; diabetic macular edema.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Preferred Reporting Items for a Systematic Review and Meta-Analyses (PRISMA) flowchart for the article selection process.
Figure 2
Figure 2
Risk of bias assessment for clinical studies involving patients affected by diabetic macular edema (DME) who received dexamethasone (DEX) intravitreal implant.
Figure 3
Figure 3
Flowchart summarizing possible determinants in patient selection for DEX implant in DME.
See this image and copyright information in PMC

References

    1. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2(1). doi:10.1186/S40662-015-0026-2 - DOI - PMC - PubMed
    1. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3):556–564. doi:10.2337/DC11-1909 - DOI - PMC - PubMed
    1. Tan GS, Cheung N, Simó R, Cheung GCM, Wong TY. Diabetic macular oedema. Lancet Diabetes Endocrinol. 2017;5(2):143–155. doi:10.1016/S2213-8587(16)30052-3 - DOI - PubMed
    1. Zhang J, Zhang J, Zhang C, et al. Diabetic Macular Edema: current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022;11(21). doi:10.3390/CELLS11213362 - DOI - PMC - PubMed
    1. Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539 - DOI - PubMed